Clinics I work with
My reviews
4.9
Selected research
-
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Neurology
-
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Lancet (London, England)
-
Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
Annals of neurology
Clinical trials
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Comparison of intrathecal synthesis of gammaglobulins in treatment-naïve relapsing MS and clinically isolated syndrome participants before and after 3 years of treatment with ocrelizumab. Intrathecal synthesis is measured by eithe...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-2069